title: [Pneumocystis and Staphylococcus aureus pulmonary co-infection after chemotherapy for lung cancer].
authors: N
authors: N
authors: Paleiron
authors: C
authors: C
authors: Tromeur
authors: E
authors: E
authors: Noel-Savina
authors: G
authors: G
authors: Quéré
authors: R
authors: R
authors: Descourt
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000532:radiotherapy / Q000556:secondary; D018288:Carcinoma, Small Cell / Q000150:complications / Q000188:drug therapy* / Q000556:secondary; D002443:Ceftriaxone / Q000008:administration & dosage / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D005047:Etoposide / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy*; D009894:Opportunistic Infections / Q000150:complications* / Q000188:drug therapy; D011020:Pneumonia, Pneumocystis / Q000150:complications* / Q000188:drug therapy; D011023:Pneumonia, Staphylococcal / Q000150:complications* / Q000188:drug therapy; D013211:Staphylococcus aureus; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D005047:Etoposide; D002443:Ceftriaxone; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D002945:Cisplatin